NRC — Cell Culture Pilot Plant ### 📋 Eligible Entities - Biopharmaceutical companies developing biologics and vaccines - Biotech SMEs requiring cell culture manufacturing capabilities - Contract Research Organizations (CROs) supporting biologics development - Academic institutions commercializing cell-based therapies - Domestic and international companies seeking Canadian manufacturing partnerships - Organizations with viable products requiring pilot-scale production validation ### 💰 Funding Details - Service Model: Fee-for-service arrangement (not a traditional grant) - Cost Structure: Clients pay NRC for pilot plant access and production services - No Direct Grant Funding: This is a cost-recovery facility, not a government subsidy program - Subsidized Rates: NRC may offer competitive pricing to Canadian innovators relative to commercial alternatives - Scale: Supports batches from development through commercial pilot quantities - Payment Terms: Negotiated per project basis ### 🛠️ Approved Expenses - Cell line development and optimization using CHO, HEK 293, and other approved systems - Process development for biologics and vaccine production - Scale-up activities from lab to pilot plant scale - Bioreactor operations and fermentation management - Quality testing and characterization of produced biologics - GMP-compliant manufacturing support for clinical/commercial batches - Technology transfer and process documentation - Analytical method development and validation ### ⚠️ Conditions & Milestones - Project Evaluation: Feasibility assessment required before engagement - Technical Viability: Product must be suitable for the available cell expression systems - Capacity Availability: Access dependent on NRC pilot plant scheduling - Regulatory Compliance: Client responsible for regulatory strategy; NRC supports GMP-quality production - Intellectual Property: Standard NRC service agreements apply; IP typically retained by client - Confidentiality: Formal confidentiality agreements required - Timeline: Project duration varies; typically 6–24 months depending on complexity - Reporting: Regular progress updates and batch documentation provided - **Success
About this program
Fee-for-service cell culture pilot plant offering development and scale-up for the production of biologics and vaccines using CHO, HEK 293 and other animal cell expression systems.
Ask AI about this Grant
Instant Eligibility Answers
Eligibility Match
Log in to automatically cross-reference this grant against your business profile and province.Check Compatibility